FDA Office of Hematology and Oncology Products is now Office of Oncologic Diseases November 08, 2019Vol.45 No.42By Matthew Bin Han Ong
Sharpless returns to NCI; Hahn to be nominated FDA commissioner; Giroir assumes acting role November 08, 2019Vol.45 No.42By Alexandria Carolan
Texas votes to keep CPRIT open with another $3 billion in state funding November 08, 2019Vol.45 No.42By Matthew Bin Han Ong
Conversation with The Cancer Letter Purdue’s Thompson: Lomustine establishes proof of principle for resolving cancer drug shortages November 08, 2019Vol.45 No.42By Paul Goldberg
Lomustine’s path from unavailable but cheap to plentiful but expensiveNeeded: A better manufacturing method November 08, 2019Vol.45 No.42By Paul Goldberg
Drugs & Targets FDA approves indication for Zejula in advanced ovarian, fallopian tube, or primary peritoneal cancer October 25, 2019Vol.45 No.40
Drugs & Targets FDA approves test to identify patients eligible for treatment with Zejula in late-line Ovarian Cancer October 25, 2019Vol.45 No.40
Drugs & Targets European Commission approves dosing schedules for Opdivo in melanoma October 25, 2019Vol.45 No.40
Drugs & Targets FDA approves Fast Track designation for bemcentinib in AML indication October 25, 2019Vol.45 No.40
Drugs & Targets Abernethy, Shuren, issue statement on FDA breast implant labelling guidance October 25, 2019Vol.45 No.40
